Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalEDTXF 10 Current Ratio is 0.06 as of Mar. 2026, which is 98% below its 10-year median of 2.68. GuruFocus rates EDTXF with a GF Score™ of 10/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 98.12% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Spectral Medical's current ratio for the quarter that ended in Mar. 2026 was 0.06.
Spectral Medical has a current ratio of 0.06. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Spectral Medical has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Spectral Medical's Current Ratio or its related term are showing as below:
EDTXF'
s Current Ratio Range Over the Past 10 Years
Min: 0.06 Med: 2.68 Max: 12.08
Current: 0.06
During the past 13 years, Spectral Medical's highest Current Ratio was 12.08. The lowest was 0.06. And the median was 2.68.
EDTXF's Current Ratio is ranked worse than 98.12% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs EDTXF: 0.06
Spectral Medical (OTCPK:EDTXF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Spectral Medical Current Ratio Related Terms
Spectral Medical Current Ratio Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Spectral Medical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Current Ratio distribution charts can be found below:
* The bar in red indicates where Spectral Medical's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (EDTXF) has a Current Ratio of 0.06 as of Mar. 2026. This is 98% below median its historical median of 2.68. Over the past decade, Spectral Medical's Current Ratio has ranged from 0.06 to 12.08. According to the industry distribution chart, Spectral Medical ranks #209 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 98.1%.
Is Spectral Medical's Current Ratio too high?
Spectral Medical's current Current Ratio of 0.06 is 98% below median its 10-year median of 2.68. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 12.08. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Spectral Medical's value of 0.06 is 97.1% below this industry median. Based on the distribution chart, Spectral Medical ranks #209 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #209 out of 213 companies for Current Ratio. This places Spectral Medical in the lower half of its industry. The industry median Current Ratio is 2.10. Spectral Medical's value of 0.06 is 97.1% below this benchmark. Historically, Spectral Medical's own Current Ratio has ranged from 0.06 to 12.08 over the past decade. While the company's 10-year median is 2.68 vs. the industry median of 2.10, Spectral Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spectral Medical's current Current Ratio of 0.06 is 97.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Current Ratio is 0.06, which is 98% below median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.95 — trading 46.2% above its estimated fair value. The current Current Ratio is 0.06, which is 98% below median its 10-year median of 2.68 and 97.1% below the Medical Diagnostics & Research industry median of 2.10. Spectral Medical's overall GF Score™ is 10/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current Current Ratio is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (EDTXF) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of $0.95 is trading 46.2% above its estimated GF Value™ of $0.65.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for EDTXF:
Current Ratio: 0.06 (98% below median its 10-year median of 2.68)
GF Value™: $0.65 vs. price of $0.95 (46.2% above fair value)
Industry Position: 97.1% below the Medical Diagnostics & Research median (#209 of 213)
No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
10GF Score
Get the complete analysis for EDTXF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDTXF has been successfully added to your 
